prikaz prve stranice dokumenta Personalizing health care: feasibility and future implications
  Download
PDF 690.72 KB
Scientific paper - Review paper
Personalizing health care: feasibility and future implications
BMC Medicine, 11 (2013), 1; 179. https://doi.org/10.1186/1741-7015-11-179
Godman, Brian; Finlayson, Alexander E; Cheema, Parneet K; Zebedin-Brandl, Eva; Gutiérrez-Ibarluzea, Inaki; Jones, Jan; Malmström, Rickard E; Asola, Elina; Baumgärtel, Christoph; Bennie, Marion; Bishop, Iain; Bucsics, Anna; Campbell, Stephen; Diogene, Eduardo; Ferrario, Alessandra; Fürst, Jurij; Garuoliene, Kristina; Gomes, Miguel; Harris, Katharine; Haycox, Alan; Herholz, Harald; Hviding, Krystyna; Jan, Saira; Kalaba, Marija; Kvalheim, Christina; Laius, Ott; Lööv, Sven-Ake; Malinowska, Kamila; Martin, Andrew; McCullagh, Laura; Nilsson, Fredrik; Paterson, Ken; Schwabe, Ulrich; Selke, Gisbert; Sermet, Catherine; Simoens, Steven; Tomek, Dominik; Vlahović-Palčevski, Vera; Voncina, Luka; Wladysiuk, Magdalena; van Woerkom, Menno; Wong-Rieger, Durhane; Zara, Corrine; Ali, Raghib; Gustafsson, Lars L More authors...

Cite this document

Godman, B., Finlayson, A. E., Cheema, P. K., Zebedin Brandl, E., Gutiérrez Ibarluzea, I., Jones, J. ... Gustafsson, L. L. (2013). Personalizing health care: feasibility and future implications. BMC Medicine, 11. (1). doi: 10.1186/1741-7015-11-179

Godman, Brian, et al. "Personalizing health care: feasibility and future implications." BMC Medicine, vol. 11, no. 1, 2013. https://doi.org/10.1186/1741-7015-11-179

Godman, Brian, Alexander E Finlayson, Parneet K Cheema, Eva Zebedin Brandl, Inaki Gutiérrez Ibarluzea, Jan Jones, Rickard E Malmström, et al. "Personalizing health care: feasibility and future implications." BMC Medicine 11, no. 1 (2013). https://doi.org/10.1186/1741-7015-11-179

Godman, B., et al. (2013) 'Personalizing health care: feasibility and future implications', BMC Medicine, 11(1). doi: 10.1186/1741-7015-11-179

Godman B, Finlayson AE, Cheema PK, Zebedin Brandl E, Gutiérrez Ibarluzea I, Jones J, and sur.. Personalizing health care: feasibility and future implications. BMC Medicine [Internet]. 2013 [cited 2024 December 05];11(1). doi: 10.1186/1741-7015-11-179

B. Godman, et al., "Personalizing health care: feasibility and future implications", BMC Medicine, vol. 11, no. 1, 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:659238. [Accessed: 05 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Personalizing health care: feasibility and future implications
AuthorBrian Godman
AuthorAlexander E Finlayson
AuthorParneet K Cheema
AuthorEva Zebedin-Brandl
AuthorInaki Gutiérrez-Ibarluzea
AuthorJan Jones
AuthorRickard E Malmström
AuthorElina Asola
AuthorChristoph Baumgärtel
AuthorMarion Bennie
AuthorIain Bishop
AuthorAnna Bucsics
AuthorStephen Campbell
AuthorEduardo Diogene
AuthorAlessandra Ferrario
AuthorJurij Fürst
AuthorKristina Garuoliene
AuthorMiguel Gomes
AuthorKatharine Harris
AuthorAlan Haycox
AuthorHarald Herholz
AuthorKrystyna Hviding
AuthorSaira Jan
AuthorMarija Kalaba
AuthorChristina Kvalheim
AuthorOtt Laius
AuthorSven-Ake Lööv
AuthorKamila Malinowska
AuthorAndrew Martin
AuthorLaura McCullagh
AuthorFredrik Nilsson
AuthorKen Paterson
AuthorUlrich Schwabe
AuthorGisbert Selke
AuthorCatherine Sermet
AuthorSteven Simoens
AuthorDominik Tomek
AuthorVera Vlahović-Palčevski
AuthorLuka Voncina
AuthorMagdalena Wladysiuk
AuthorMenno van Woerkom
AuthorDurhane Wong-Rieger
AuthorCorrine Zara
AuthorRaghib Ali
AuthorLars L Gustafsson
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Public Health and Health Care
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Pharmacology and Toxicology
Abstract (english)
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleBMC Medicine
Numberingvol. 11, no. 1, 179
e-ISSN1741-7015
DOIhttps://doi.org/10.1186/1741-7015-11-179
URN:NBNurn:nbn:hr:184:659238
Publication2013
Document URLhttp://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-179
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0) icon
Created on2021-03-10 11:38:36